Comprehensive Parkinson's Disease CRO Solutions for Drug Discovery
Overcome the challenges of Parkinson's drug discovery with Cyagen. Our integrated platform offers validated animal models and expert CRO services, providing reliable and efficient research support to scientists developing novel PD therapeutics.
An Integrated Approach to PD Research & Its Challenges
As the second most common neurodegenerative disorder, Parkinson's Disease has a significant global impact with substantial unmet medical needs. Key research bottlenecks include the need for models that accurately recapitulate the key features of synucleinopathy and the complexity of evaluating motor and non-motor symptoms.
To address these challenges, Cyagen has developed a powerful and integrated research platform. Our
portfolio of specialized synucleinopathy models, combined with comprehensive in vivo and in vitro
services detailed below, provides the critical tools scientists need to overcome these hurdles and
accelerate their PD discovery programs.
{{ item.title }}
{{static_tabs[0].title}}
Disease-Relevant Induced Parkinson disease (PD) model
Cyagen provides multiple disease-relevant induced PD models to support
synucleinopathy research, neurotoxin-based pharmacology studies, and behavioral validation
workflows.
| Model Name | Key Mechanism | Pathology & Clinical Relevance | Action |
|---|---|---|---|
| AAV-induced model (AAV9.CNS-Mut-CAG-hαSyn-A53T) | Single IV injection of a blood-brain barrier–penetrating AAV9 variant (Cyagen's CNS-Mut capsid) driving pan-neuronal expression of human α-synuclein carrying the familial A53T mutation. | Generates progressive motor impairment, broad brain expression of human α-synuclein, and phosphorylated α-synuclein pathology, supporting PD/synucleinopathy studies | |
| WT or hSNCA (3'UTR) + PFF | Stereotaxic intracranial injection of α-synuclein preformed fibrils (PFF or PFF-p129) into the right dorsal striatum | Supports investigation of α-synuclein seeding-related pathology and long-term functional changes in WT and hSNCA-background mice | |
| 6-OHDA induced model | Combined stereotaxic injection of the selective dopaminergic neurotoxin 6-OHDA into both substantia nigra (3 µg) and striatum (3 µg) to achieve consistent nigrostriatal lesioning. | Models dopaminergic neurodegeneration and unilateral motor deficits | |
| Acute MPTP-induced model | Four intraperitoneal injections of MPTP·HCl at 2-hour intervals on a single day, producing rapid dopaminergic neurotoxicity. | Produces acute locomotor impairment suitable for short-term pharmacology studies and response testing with open-field endpoints | |
| Subacute MPTP-induced model | 12-day consecutive intraperitoneal injections of MPTP·HCl combined with IV therapeutic dosing every 3 days to model chronic dopaminergic degeneration. | Supports evaluation of progressive PD-like behavioral deficits and drug-response studies under a more extended toxicant exposure regimen |
Relevant Mouse Model
| Catalog Number | Name | Base Strain | Research Application | Action |
|---|---|---|---|---|
| {{ value.product_num || "--" }} | {{ value.product_name || "--" }} | {{ value.product_strain || "--" }} |
|
+
|
Next Page
Disease-Relevant Cell Lines for PD Research
Cyagen offers a diverse array of rigorously validated cell lines optimized for
neurodegenerative disease research. These cellular models provide researchers with robust,
scalable in vitro systems for high-throughput screening, mechanistic studies, and preliminary
neurotoxicity assessments prior to transitioning to animal models.
| Product Type | Product Name | Genetic Modification | Service ID | Cell Format | Cell Format |
|---|---|---|---|---|---|
| DIFF | iPSC-DA (Dopaminergic Neurons) | — | SY-iD-00001 | `Differentiated cells | Available |
| DIFF | iPSC-NPC (Neural Progenitor Cells) | — | SY-iN-00001 | Differentiated cells | Available |
| MU | MU-iPSC-LRRK2 (p.G2019S) | Human LRRK2 (p.G2019S) | SY-iMU-00026 | iPSC | In development |
| MU | MU-iPSC-SNCA (p.A53T) | Human SNCA (p.A53T) | SY-iMU-00027 | iPSC | In development |
| MU | MU-iPSC-SNCA (p.A30G) | Human SNCA (p.A30G) | SY-iMU-00028 | iPSC | In development |
| MU | MU-iPSC-SNCA (p.E46K) | Human SNCA (p.E46K) | SY-iMU-00029 | iPSC | In development |
| MU | MU-iPSC-GBA1 (p.R159W) | Human GBA1 (p.R159W) | SY-iMU-00030 | iPSC | In development |
| MU | MU-iPSC-PINK1 (p.Q456X) | Human PINK1 (p.Q456X) | SY-iMU-00032 | iPSC | In development |
{{static_tabs[1].title}}
Precision Drug Administration
Our team is highly experienced in the precision dosing and administration
methods critical for PD research, including routes that target the central nervous system.
- Systemic Delivery: Intravenous (tail vein), Intraperitoneal, Subcutaneous, etc.
- CNS-Targeted Delivery: Stereotactic brain injection into key regions like the substantia nigra or striatum.
Neurobehavioral Assessment for PD
We provide a battery of behavioral paradigms essential for evaluating the core motor and
non-motor deficits associated with Parkinson's Disease.
| Behavioral Domain | Recommended Tests for PD Research | Function Tested |
|---|---|---|
| Motor Function & Coordination | Rotarod Test | Motor coordination, balance, ataxia |
| Pole Test | Bradykinesia, motor coordination | |
| Grip Strength | Muscle strength | |
| Gait Analysis | Fine motor coordination and balance | |
| Cognitive & Psychiatric | Open Field Test | Spontaneous locomotor activity-related behavior |
{{static_tabs[2].title}}
We offer a focused suite of analytical services to investigate the core
pathological and molecular features of Parkinson's Disease, and to evaluate the efficacy of
your therapeutic candidates.
| Analysis Category | Specific Services | Key Applications & Targets in PD Research |
|---|---|---|
| Pathology & Biomarker Analysis | Histology & IHC/IF | Visualize and quantify key pathological hallmarks, including α-synuclein aggregates (pS129, total) and assess dopaminergic neuron health and loss via Tyrosine Hydroxylase (TH) staining. |
| ELISA & Immunoassays | Accurately quantify levels of total and aggregated α-synuclein in brain tissue and other biological samples. | |
| Neurotransmitter Analysis (HPLC) | Measure the levels of dopamine and its key metabolites (DOPAC, HVA) in the striatum and other relevant brain regions to assess the integrity of the nigrostriatal pathway. | |
| Gene & Protein Expression | Western Blot | Assess changes in α-synuclein (SNCA) protein levels, post-translational modifications (e.g., phosphorylation), and aggregation status. |
| RT-PCR & qPCR | Analyze the expression of the SNCA gene and other relevant therapeutic or pathological target genes to understand mechanistic changes. |
Case Studies
Our models undergo rigorous validation to ensure they are robust and reliable tools for your research.
Explore our case studies below, which highlight the successful characterization of our humanized genetic
models and our expertise in conducting preclinical drug efficacy studies.
{{ item.label }}
{{v2.label}}
{{item.context}}
- {{v2}}
{{v2.context}}
{{item.title}}
- {{item}}
{{ item.context }}
Why Partner with Cyagen?
Comprehensive Model Solutions
Gain access to validated humanized SNCA models and leverage our expertise in developing custom models for other PD-related targets.
Integrated Efficacy Platform
Utilize our one-stop services—from motor function assessment to terminal neurochemical and pathological analysis.
Data-Driven Decision Support
Our stringent quality control and commitment to reproducibility deliver reliable data for your project decisions.
Expert-Led Study Design
Collaborate with our senior scientists for end-to-end support, from model selection to customized protocol design.
Related Resources
Events & Webinars
PEGS Boston Essential Protein & Antibody Engineering Summit 2026
View Details
Promotional Campaign
Flash Drop — Ready-to-Ship KO/CKO Mice
View Details
Blogs & Insights
Breakthrough Glaucoma Research: Leveraging ANGPTL7 Humanized Models for Gene Therapy
View Details
Resource Valut
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
View Details
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.